Multidisciplinary

Top Medical News
DAPT with cilostazol reduces stroke recurrence without raising bleeding risk
an hour ago
Dual antiplatelet therapy (DAPT) using cilostazol appears to be more beneficial than single antiplatelet therapy, with the results of a study suggesting that DAPT helps lower the incidence of ischemic stroke recurrence without increasing the risk of severe or life-threatening bleeding.
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
Roshini Claire Anthony, 16 hours ago

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

Radiation therapy may raise colorectal cancer risk among Hodgkin's lymphoma survivors
16 hours ago
Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.
Isolated anti-HBc positivity ups liver-related death risk
18 hours ago
Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.
Pharmacist-led collaborative gout clinic helps patients achieve serum uric acid goals
Stephen Padilla, 19 hours ago
A collaborative clinic led by a pharmacist helps patients with gout to attain better clinical outcomes in the management of their condition, even in the presence of renal impairment, reports a Singapore study. The clinic provides safe, stepwise increments of urate-lowering therapy (ULT) in addition to serum uric acid (SUA) monitoring and adherence reinforcement through frequent initial visits.
Repeated low-level red-light therapy helps prevent myopia progression in children
20 hours ago
Treatment with repeated low-level red-light (RLRL) therapy with 100-percent power results in significant reduction in myopia progression over 6 months in myopic children when compared to a sham device with 10-percent original power, a China study has shown. In addition, the RLRL therapy is well tolerated and does not lead to serious adverse effects (AEs)
SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
Audrey Abella, 21 hours ago
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
Special Reports
SARS-CoV-2 Variants: Everything you need to know
01 Feb 2023
The COVID-19 pandemic continues to evolve with the emergence of new SARS-CoV-2 variants. The variants of concern have the potential to impact the transmissibility, virulence, and clinical presentation of the disease, affecting the epidemiology, public health measures, and diagnostic and therapeutic options. Mutations in the spike protein of the virus have increased its ability to infect humans and evade neutralization by natural or immunisation-induced antibodies. The highly mutated Omicron variant of SARS-CoV-2 has multiple sublineages with varying transmissibility and immune evasion potential. Pre-exposure prophylaxis plays a crucial role in protecting the immunocompromised populations against severe disease; however, the rapidly changing landscape of the variants poses a major challenge to the current and future effectiveness of pre-exposure prophylactic monoclonal antibodies.
Knee osteoarthritis management
with ESCEO guidelines:
The importance of a multimodal approach
01 Feb 2023
At the Pain Masterclass Tour Symposium, held at Le Meridien Kuala Lumpur, Prof Dr Reginster discussed the ESCEO guidelines for the management of knee osteoarthritis (OA) in improving the quality of life of individuals suffering from this disease, and presented information and evidence affirming the efficacy of the novel symptomatic slow-acting drugs for OA(SYSADOAs), patented crystalline glucosamine sulfate (pCGS).
The role of oral antivirals in COVID-19 treatment: Who, when, and how?
Dr. Roger Paredes, Dr. Nicola Petrosillo, Dr. Petrick Periyasamy, 30 Jan 2023

Though most countries have eased pandemic restrictions, there is no room for complacency in managing COVID-19, which continues to cause significant morbidity and mortality.

At a recent symposium, esteemed experts Dr Roger Paredes, Head of Department of Infectious Diseases at the Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain, and Dr Nicola Petrosillo, Head of the Infection Prevention and Control and Infectious Disease Service at University Hospital Campus Bio-Medico, Rome, Italy, gave global perspectives on the continuing unmet needs in the COVID-19 outpatient landscape and discussed the role of antiviral treatment options in patients at risk of progressing to severe COVID-19. Dr Petrick Periyasamy, Head of Infectious Diseases Unit, Medical Department, UKM Medical Centre, Kuala Lumpur, Malaysia, chaired the session.

Antimicrobial resistance: Next global, public health threat after COVID-19
Pank Jit Sin, 10 Jan 2023
As the dust settles from the SARS-CoV-2 pandemic, the lurking threat of antimicrobial resistance (AMR) once again rears its ugly head. Weighing in on this topic is Professor Dr Sasheela Sri La Sri Ponnampalavanar, Infectious Disease Professor, University Malaya Medical Centre (UMMC). Below is an excerpt from her bylined piece titled ‘Tackling the Next Global and Public Health Threat After COVID-19 – Antimicrobial Resistance (AMR).’
Simplicity with linagliptin: Efficacy and safety in a broad range
of patients with type 2 diabetes mellitus including those
01 Jan 2023
At a recent webinar jointly organised by the Malaysian Medical Association and Boehringer Ingelheim celebrating a decade-long of linagliptin use in patients with type 2 diabetes mellitus (T2DM), two distinguished speakers addressed the efficacy and safety of linagliptin in a broad range of patients with T2DM; updates from recent clinical trials and real-world evidence were discussed.
Multipathogen testing an essential part of Test-Target-Treat strategy for respiratory illnesses
Dr. Mohan Ravuru, Dr. Johnny Sinon, Assoc Prof. Nuntra Suwantarat, 16 Dec 2022

At a recent webinar, experts discussed the paradigm shift in respiratory illnesses and treatment practices as the COVID-19 pandemic transitions to an endemic phase. The late Dr Mohan Ravuru, Physician Researcher and former Asia Pacific Medical Director, Abbott, Dr Johnny Sinon, Senior Emergency Physician from Makati Medical Center, Philippines, and Associate Professor Nuntra Suwantarat, Infectious Disease Specialist, from Chulabhorn International College of Medicine, Thammasat University, Thailand, delivered informative presentations and engaged the audience through a stimulating panel discussion.

Among the topics covered were the ‘immunity debt’ phenomenon leading to potential epidemics, challenges in the differential diagnosis of COVID-19 and influenza, and the importance of point-of-care, multipathogen testing as a part of the Test-Target-Treat strategy in respiratory diseases.

A retrospective case series of ovarian stimulation
with follitropin delta in a mixed regimen with HP-hMG:
An interim analys
05 Dec 2022
Studies have shown that controlled ovarian stimulation (COS) supplementation with human chorionic gonadotropin (hCG)-driven luteinising hormone activity such as highly purified human menopausal gonadotropin (HP-hMG) (Menopur®) resulted in a significantly higher proportion of top-quality embryos and numbers of good-quality blastocysts compared with recombinant follicle-stimulating hormone (rFSH) alone. Regimens that combine FSH and hMG are often referred to as ‘mixed protocols’ and have been widely used for ovarian stimulation in the past decade. This single-centre, retrospective case series study aims to assess the efficacy of COS with follitropin delta in a mixed protocol regimen with HP-hMG in terms of the number of top-quality embryos and clinical pregnancy rate among Malaysian patients in a reproductive medicine clinic.
Conference Reports
Does LMWH improve live birth rate in women with inherited thrombophilia and miscarriage history?
Roshini Claire Anthony, 06 Feb 2023

The use of low-molecular-weight heparin (LMWH) during pregnancy did not increase the likelihood of live birth compared with standard surveillance in women with inherited thrombophilia who have experienced multiple miscarriages, according to a multinational study presented at ASH 2022.

SPOTLIGHT shines on zolbetuximab-chemo potential for gastric/GEJ cancer
Audrey Abella, 06 Feb 2023
A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.
130/80 home BP equivalent to clinic BP for stage 1 hypertension
Stephen Padilla, 03 Feb 2023
The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Tislelizumab–chemotherapy combo poised as new first-line option for advanced gastric cancer
Jairia Dela Cruz, 03 Feb 2023
Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.
Palliative RT relieves pain in end-stage liver cancer
Stephen Padilla, 02 Feb 2023
Treatment with single fraction radiation therapy (RT) results in lesser hepatic pain in most patients with end-stage hepatocellular carcinoma (HCC) or liver metastases, according to a study presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).
Preop chemotherapy confers survival advantage in colorectal cancer with liver metastasis
Jairia Dela Cruz, 02 Feb 2023
Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).
Durable benefits with beti-cel therapy in beta-thalassaemia
Elvira Manzano, 26 Jan 2023
One-time ex-vivo gene therapy with betibeglogene autotemcel (beti-cel) reduces the need for transfusion in patients with transfusion-dependent beta-thalassaemia in an analysis of studies presented at ASH 2022.